TAS2R30

Across TCGA pan-cancer cohorts, TAS2R30 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of TAS2R30’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where TAS2R30 RNA is repressed in tumor relative to normal tissue. In most cancer types TAS2R30 is over-expressed in tumor, although a few such as THCA and STAD show the opposite, repressed pattern.

THCA, STAD, and KIRC are the cancer types where TAS2R30 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TAS2R30 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	II,III,IV	−0.064	<.001	7	view →
STAD	Male	IV	−0.145	.001	1	view →
KIRC	All	All	+0.018	.025	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

TAS2R30–THCA

Open the THCA breakdown →